高级搜索

卵巢癌P-糖蛋白、GST-π、P53、P185表达对近期化疗效果的影响

杨林, 李学汤, 诸亚君, 刘丽影

杨林, 李学汤, 诸亚君, 刘丽影. 卵巢癌P-糖蛋白、GST-π、P53、P185表达对近期化疗效果的影响[J]. 肿瘤防治研究, 1998, 25(4): 254-256.
引用本文: 杨林, 李学汤, 诸亚君, 刘丽影. 卵巢癌P-糖蛋白、GST-π、P53、P185表达对近期化疗效果的影响[J]. 肿瘤防治研究, 1998, 25(4): 254-256.
Yang Lin, . Expression of P-GP,GST-π,p53 and P185 in ovarian carcinomas and relationship with response to chemotherapy[J]. Cancer Research on Prevention and Treatment, 1998, 25(4): 254-256.
Citation: Yang Lin, . Expression of P-GP,GST-π,p53 and P185 in ovarian carcinomas and relationship with response to chemotherapy[J]. Cancer Research on Prevention and Treatment, 1998, 25(4): 254-256.

卵巢癌P-糖蛋白、GST-π、P53、P185表达对近期化疗效果的影响

Expression of P-GP,GST-π,p53 and P185 in ovarian carcinomas and relationship with response to chemotherapy

  • 摘要: 目的:评价卵巢癌P-糖蛋白、P53、P185表达对近期化疗效果的影响及相互关系。方法:免疫组织化学ABC法检测49例卵巢癌P-糖蛋白、GST-π、P53、P185表达。结果:1.卵巢癌P-糖蛋白、GST-π、P53、P185表达阳性者的近期化疗有效率分别为14.3%。27.3%、41、67%、24、63%,而表达阴性者的近期化疗有效率分别为53.6%(P0.05)、75.0%(P<0.005)。2.P-糖蛋白、P185的表达存在相关性(P<0.05)。结论:卵巢癌P-糖蛋白、GST-π、P185的表达明显影响其近期化疗效果。P-糖蛋白、P185表达的相关性值得进一步研究。

     

    Abstract: To evaluate the response to chemotherapy and relationship on expressionfo P-GP, GST-π, P53, P185in ovarian carcinomas.methods: lmmunohistochemical technique ABC was used to detect P-GP,GST-π,P53, P185content in 49 cases of ovarian carcinomas.results: 1.The response rates to chemotherapy of patients with positive stainingof P-GP, GST-π, P53, P185 were 14% 、27.3%、 41.7%、 24.3% respectively: but thoserates of patients with negative staining were 53.6% (P<0.005)、 56.3% (P<0.005)、48.2% (P<0.05)、 75.0% (P<0.005) respectively.2.There was a close correlation between expression of P-GP and P185 (P<0.05).conclusions: Expression of P GP,GST-π,P53and P185 affect the recent results of chemotherapy obviously in ovarian carcinomas.There was a researched value in depth on relationship between expression of P-GP and P185.

     

  • [1] Bradlay G, Juranka DF, Ling V. Machanism of multidrugresistance. Biochem. Biophys. Acta, 1988, 948:87
    [2] Hamada S, Kamada M, Furumoto H, et al. Expression ofglutathion S-transferase-piin human ovarian cancer as anindictor of resistance to chemotherapy. Gynecol Oncol, 1994,52:313
    [3] Tsai CM,Chang KT, Pemg RP, et s1,Correlation of in-trinsic chemresistance of non-small-cell cancer cell lineswith HER-2ineu gene expression but not with ras genemutatious. J NATI Cancer Inst,1988, 85:897
    [4] Chin K. Ueda K,Pstan 1,et al. Modulation of activity ofthe promoter of the human MDRI gene by ras and 1353. Sci--ence, 1992,255:459
    [5] 倪灿荣主编.免疫组织化学实验新技术及应用.北京科学技术出版社.p128
    [6] Rubin SC,Finstad Cl,Hoskins WJ,et al. Expression ofP-glycoprotein of MDR, (P-glycoprotein) gene expres-sion in ovarian and small-cell lung carcinoma. J Natl Can-cer lnst, 1992, 84.1486
    [7] Murphy D, Mc Crown AT, Hall A, et al. Clutathione S-transferase activity and isoenzyme distribution in ovariantumor biopsies taken before or after cytotoxic chemothera-py. Br J Cancer, 1992, 66:937
    [8] Baekelandt M,Kristensen G, Holm R, et al. P-GP ex-pression as a possible marker for response to cisplatin/epirubicin as first line treatment in advanced ovarian can-cer. 1st international conferance on reversal of multidrugresistance in cancer: abstracts. Anticancer drug 1994, 5(suppl 1):59
    [9] Felip E, Campo JMD, Rubio D, et al. C)verexpresston ofC-erbB/2 in eoithelial ovarian cancer-prognotic value andrelationship with response to chemotherapy. Cancer, 199575:2147
计量
  • 文章访问数:  935
  • HTML全文浏览量:  24
  • PDF下载量:  227
  • 被引次数: 0
出版历程
  • 刊出日期:  1998-08-04

目录

    /

    返回文章
    返回
    x 关闭 永久关闭